PTCL
Clinical trials for PTCL explained in plain language.
Never miss a new study
Get alerted when new PTCL trials appear
Sign up with your email to follow new studies for PTCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a smart drug spare healthy cells while killing lymphoma?
Disease control Not yet recruitingThis trial is testing an experimental drug called FG-M131 in people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. FG-M131 is designed to target and destroy cancerous T cells that carry a marker called TRBC1, …
Matched conditions: PTCL
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill boost Chemo's power against a rare blood cancer?
Disease control Not yet recruitingThis trial is testing whether adding an experimental targeted drug, SHR2554, to standard chemotherapy (liposomal mitoxantrone) can improve outcomes for people with peripheral T-cell lymphoma (PTCL) who have not yet been treated. The study involves about 44 adults with certain PTC…
Matched conditions: PTCL
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for tough lymphoma: TR115 faces off against standard care
Disease control Not yet recruitingThis study tests a new drug called TR115 in about 180 adults with a rare blood cancer (T/NK-cell lymphoma) that has come back or not responded to prior treatments. Participants will receive either TR115 or one of several standard drugs. The main goal is to see if TR115 can slow c…
Matched conditions: PTCL
Phase: PHASE3 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for refractory lymphoma: tailored drug cocktail targets resistant cancer
Disease control Not yet recruitingThis study tests a new approach for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Doctors will use genetic testing of the tumor to choose a personalized combination of drugs, including an experimental drug called zeprumetostat. The goal is to…
Matched conditions: PTCL
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill aims to extend remission in rare blood cancer
Disease control Not yet recruitingThis study tests a drug called SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who have responded to initial treatment. The goal is to see if taking this pill can help keep the cancer from progressing for longer. About 30 adults who have achieved compl…
Matched conditions: PTCL
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New study aims to decode PTCL by genetic subtype
Knowledge-focused Not yet recruitingThis study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goa…
Matched conditions: PTCL
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC